Madrigal Pharmaceuticals (MDGL) Profit After Tax (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Profit After Tax data on file, last reported at -$94.4 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 28.88% year-over-year to -$94.4 million in Q1 2026; TTM through Mar 2026 was -$309.4 million, a 20.98% increase from a year earlier, with the FY2025 full-year figure at -$288.3 million, up 38.12% from the prior year.
• Profit After Tax for Q1 2026 stood at -$94.4 million, down from -$58.6 million in the prior quarter.
• Over the last five years, Profit After Tax for MDGL reached as high as -$42.3 million in Q2 2025 and fell as low as -$152.0 million in Q2 2024.
• Historically, Profit After Tax has averaged -$89.3 million across 5 years, with a median of -$85.8 million in 2023.
• Across the five-year window, Profit After Tax tumbled 91.87% in 2024 and jumped 72.18% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$85.9 million in 2022, then sank by 30.6% to -$112.2 million in 2023, then surged by 47.04% to -$59.4 million in 2024, then advanced by 1.42% to -$58.6 million in 2025, then plunged by 61.15% to -$94.4 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$94.4 million in Q1 2026, -$58.6 million in Q4 2025, and -$114.2 million in Q3 2025.